mRNA Vaccine Formulation via dTCAP Metric and Chemical Modification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The therapeutic efficacy of RNA vaccines, including mRNA vaccines, has been inconsistent due to challenges in delivering mRNA without viral or artificial replication, leading to variable immune responses and toxicity.
Innovation Solution
A novel metric, differential T cell activation potential (dTCAP), is used to evaluate mRNA vaccine quality by measuring T cell suppression and activation ratios at injection sites and draining lymph nodes, allowing for the development of formulations that achieve strong immune responses with minimal toxicity, using carriers like lipid nanoparticles and chemically modified mRNA.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If mRNA vaccines are delivered without viral or artificial replication, then safety is improved, but therapeutic efficacy becomes inconsistent
Solution Approach 1:
The patent applies parameter changes by modifying the mRNA molecule itself through chemical modifications (such as nucleoside analogs like pseudouridine or 5-methylcytidine) to alter its immunogenicity and stability parameters. These modifications enable the mRNA to achieve consistent therapeutic efficacy without requiring viral or artificial replication mechanisms, thereby maintaining safety while improving reliability.
Solution Approach 2:
The patent uses delivery carriers as intermediaries to transport the modified mRNA into target cells. These carriers (such as lipid nanoparticles or other non-viral delivery systems) mediate the delivery process, protecting the mRNA from degradation and facilitating cellular uptake without introducing viral replication mechanisms, thus resolving the contradiction between safety and efficacy.
2Reliability
If strong immune response is achieved, then therapeutic benefit is improved, but injection site toxicity increases
Solution Approach 1:
The patent modifies the mRNA parameters through chemical modifications that tune the balance between immunogenicity and toxicity. By adjusting the type and extent of nucleoside modifications, the vaccine achieves strong immune responses while reducing activation of harmful inflammatory pathways at the injection site, thereby resolving the contradiction between therapeutic benefit and local toxicity.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
High quality vaccines are identified and formulated based on a threshold differential T-cell activation potential. The vaccines are mRNA vaccines formulated in a carrier, wherein the mRNA encodes an antigen.